Skip to content

H.R. 4273 · 119th Congress (2025–2027)

Over-the-Counter Monograph Drug User Fee Amendments

This bill reauthorizes the Over-the-Counter (OTC) Monograph Drug User Fee Program (OMUFA) through FY2030 and revises certain aspects of the program, including total fees to be collected and fee due dates.

Under current law, many OTC drugs are marketed through compliance with an OTC monograph issued by the Food and Drug Administration (FDA), rather than through an approved new drug application. Monographs establish the conditions under which OTC drugs are generally recognized as safe and effective, and include ingredients, dosages, and other requirements. OMUFA permits the FDA to collect fees from OTC drug facilities and entities requesting changes to a monograph.

The bill makes certain changes to OMUFA, including by

  • revising the total facility fee revenue amount to be collected for FY2026-FY2030,
  • revising due dates for facility fees,
  • permitting the FDA to implement a one-time adjustment to facility fees if certain conditions exist, and
  • requiring the FDA to publish facility and order request fee amounts at least 60 days before the start of each fiscal year.

Finally, the bill adds as a Tier 2 OTC monograph order request a request for the addition or modification of a testing procedure applicable to a monograph drug, provided the testing procedure reflects a voluntary consensus standard with respect to pharmaceutical quality. (Requestors seeking certain kinds of changes to a monograph are awarded a period of market exclusivity if the FDA makes the requested changes; tier 2 requests are not eligible for market exclusivity.)

Show official title

To amend the Federal Food, Drug, and Cosmetic Act to revise and extend the user fee program for over-the-counter monograph drugs, and for other purposes.

Reported

This bill’s path

This is H.R. 4273’s recorded path, not a universal congressional workflow.

How bills become lawAll actions
  1. Introduced

  2. Passed House

  3. Passed Senate

  4. Sent to President

  5. Signed into law

Sponsor
Rep. Robert E. Latta (R-OH-5)
Cosponsors
3 cosponsors

3 original · 0 later

  1. Rep. Dan Crenshaw (R-TX-2)· Original · Jul 2, 2025
  2. Rep. Diana DeGette (D-CO-1)· Original · Jul 2, 2025
  3. Rep. Debbie Dingell (D-MI-6)· Original · Jul 2, 2025
Policy area
Health
Subjects
  • Congressional oversight
  • Drug safety, medical device, and laboratory regulation
  • User charges and fees

On this page

Timeline

i

In chronological order. Major procedural acts are shown in full. Committee work and ordinary amendments fold in place where they happened, so they do not jump the sequence or stretch the timeline.

  1. Introduced in House

    Document: Introduced in House

    Sources
  2. Latest
    ▸ 4 committee actions · Jul 2, 2025 – Sep 17, 2025
    1. Referred to committee

      Referred to the House Committee on Energy and Commerce.

      Sources
    2. Markup session held

      Committee Consideration and Mark-up Session Held

      Sources
    3. Ordered reported

      Ordered to be Reported (Amended) by the Yeas and Nays: 51 - 0.

      Sources
    4. Reported by committee

      Reported (Amended) by the Committee on Energy and Commerce. H. Rept. 119-300.

      Sources

Committees

  1. HouseEnergy and CommerceReferred Jul 2, 2025 · Markup Jul 23, 2025 · Reported Sep 17, 2025H. Rept. 119-300
    1. Jul 23, 2025 · Markup

    1. H. Rept. 119-300 · Sep 17, 2025 · Over-the-Counter Monograph Drug User Fee Amendments

Text & titles

i

Each distinct name Congress.gov recorded, once. Official, short, display, and popular titles stay distinct when the wording differs. The same wording is not repeated for every text version.

Text versions
VersionDateLinks
Introduced in House
Reported in House
Titles (2)
  1. Over-the-Counter Monograph Drug User Fee Amendments

    Display title, Short title · Reported in House, Introduced in House

  2. To amend the Federal Food, Drug, and Cosmetic Act to revise and extend the user fee program for over-the-counter monograph drugs, and for other purposes.

    Official title · Introduced in House